Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response - Nature Reviews Cancer
- ️Moeller, Benjamin
- ️Sun Jun 01 2008
Virchow, R. Die Krankhaften Geschwulste (August Hirschwald, Berlin, 1863). The first report that vascular structures in tumours are abnormal.
Goldman, E. Growth of malignant disease in man and the lower animals with special reference to vascular system. Proc. R. Soc. Med. 1, 1 (1907).
Warren, B. A. in Tumor Blood Circulation: Angiogenesis, vascular morphology and blood flow of experimental and human tumors (ed. Peterson, H. I.) 1–48 (CRC Press, Boca Raton, 1979).
Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182–1186 (1971). The first to suggest that inhibition of tumour angiogenesis could have therapeutic benefit.
Vaupel, P., Thews, O., Kelleher, D. K. & Hoeckel, M. Oxygenation of human tumors: the Mainz experience. Strahlenther. Onkol. 174 (Suppl. 4), 6–12 (1998).
Braun, R. D., Lanzen, J. L., Snyder, S. A. & Dewhirst, M. W. Comparison of tumor and normal tissue oxygen tension measurements using OxyLite or microelectrodes in rodents. Am. J. Physiol. Heart Circ. Physiol. 280, H2533–H2544 (2001).
Semenza, G. L. Targeting HIF-1 for cancer therapy. Nature Rev. Cancer 3, 721–732 (2003).
Wang, G. L. & Semenza, G. L. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc. Natl Acad. Sci. USA 90, 4304–4308 (1993).
Semenza, G. L. & Wang, G. L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol. 12, 5447–5454 (1992). Discovered that HIF1 is the oxygen-sensitive transcription factor that controls erythropoeitin synthesis.
Jaakkola, P. et al. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468–472 (2001). The first to report that prolyl hydroxylation, which requires molecular oxygen, is the fundamental mechanism for stabilizing HIF1α under hypoxic conditions.
Ohh, M. et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nature Cell Biol. 2, 423–427 (2000). The first to report that oxygen-dependent degradation of HIF1α occurs by recognition of the protein by the VHL complex
Thurman, R. G., Ji, S., Matsumura, T. & Lemasters, J. J. Is hypoxia involved in the mechanism of alcohol-induced liver injury? Fundam. Appl. Toxicol. 4, 125–133 (1984).
Wangsa-Wirawan, N. D. & Linsenmeier, R. A. Retinal oxygen: fundamental and clinical aspects. Arch Ophthalmol. 121, 547–557 (2003).
Haroon, Z. A., Raleigh, J. A., Greenberg, C. S. & Dewhirst, M. W. Early wound healing exhibits cytokine surge without evidence of hypoxia. Ann. Surg. 231, 137–147 (2000).
Hale, L. P., Braun, R. D., Gwinn, W. M., Greer, P. K. & Dewhirst, M. W. Hypoxia in the thymus: role of oxygen tension in thymocyte survival. Am. J. Physiol. Heart. Circ. Physiol. 282, H1467–1477 (2002).
Samoszuk, M. K., Walter, J. & Mechetner, E. Improved immunohistochemical method for detecting hypoxia gradients in mouse tissues and tumors. J. Histochem. Cytochem. 52, 837–839 (2004).
Henquell, L., Odoroff, C. L. & Honig, C. R. Coronary intercapillary distance during growth: relation to PtO2 and aerobic capacity. Am J. Physiol. 231, 1852–1859 (1976).
Parmar, K., Mauch, P., Vergilio, J. A., Sackstein, R. & Down, J. D. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc. Natl Acad. Sci. USA 104, 5431–5436 (2007).
Arteel, G. E., Thurman, R. G., Yates, J. M. & Raleigh, J. A. Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Br. J. Cancer 72, 889–895 (1995).
Laughlin, K. M. et al. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2, 2, 3, 3, 3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors. J. Pharmacol. Exp. Ther. 277, 1049–1057 (1996).
Rosmorduc, O. et al. Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis. Am. J. Pathol. 155, 1065–1073 (1999).
Houck, K. A., Leung, D. W., Rowland, A. M., Winer, J. & Ferrara, N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267, 26031–26037 (1992).
Fannon, M. et al. Binding inhibition of angiogenic factors by heparan sulfate proteoglycans in aqueous humor: potential mechanism for maintenance of an avascular environment. FASEB J. 17, 902–904 (2003).
Chou, S. C., Azuma, Y., Varia, M. A. & Raleigh, J. A. Evidence that involucrin, a marker for differentiation, is oxygen regulated in human squamous cell carcinomas. Br. J. Cancer 90, 728–735 (2004).
Zhu, Y. et al. Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene 24, 6555–6563 (2005).
Huang, J. H. et al. Requirements for T lymphocyte migration in explanted lymph nodes. J. Immunol. 178, 7747–7755 (2007).
Li, F. et al. Regulation of HIF-1α stability through S-nitrosylation. Mol. Cell 26, 63–74 (2007). This paper proved that nitrosylation of a cysteine residue in the oxygen-dependent degradation domain of HIF1α can prevent its degradation under aerobic conditions.
Chandel, N. S. et al. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1α during hypoxia: a mechanism of O2 sensing. J. Biol. Chem. 275, 25130–25138 (2000). The first report suggesting that reactive oxygen species may be responsible for stabilizing HIF1α under hypoxic conditions.
Guzy, R. D. et al. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab. 1, 401–408 (2005).
Bell, E. L. et al. The Qo site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production. J. Cell Biol. 177, 1029–1036 (2007).
Ignarro, L. J. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J. Physiol. Pharmacol. 53, 503–514 (2002).
Pryor, W. A. et al. Free radical biology and medicine: it's a gas, man! Am. J. Physiol. Regul. Integr. Comp. Physiol. 291, R491–511 (2006).
Moncada, S. & Higgs, E. A. The discovery of nitric oxide and its role in vascular biology. Br. J. Pharmacol. 147 (Suppl. 1), S193–S201 (2006).
Tozer, G. M. & Everett, S. A. Nitric oxide in tumor biology and cancer therapy. Part 2: Therapeutic implications. Clin. Oncol. (R. Coll. Radiol.) 9, 357–364 (1997).
Tozer, G. M. & Everett, S. A. Nitric oxide in tumour biology and cancer therapy. Part 1: Physiological aspects. Clin. Oncol. (R. Coll. Radiol.) 9, 282–293 (1997).
BelAiba, R. S. et al. Redox-sensitive regulation of the HIF pathway under non-hypoxic conditions in pulmonary artery smooth muscle cells. Biol. Chem. 385, 249–257 (2004).
Page, E. L., Chan, D. A., Giaccia, A. J., Levine, M. & Richard, D. E. Hypoxia-inducible factor-1α stabilization in nonhypoxic conditions: role of oxidation and intracellular ascorbate depletion. Mol. Biol. Cell 19, 86–94 (2008).
Mateo, J., Garcia-Lecea, M., Cadenas, S., Hernandez, C. & Moncada, S. Regulation of hypoxia-inducible factor-1α by nitric oxide through mitochondria-dependent and -independent pathways. Biochem. J. 376, 537–544 (2003).
Sumbayev, V. V., Budde, A., Zhou, J. & Brune, B. HIF-1 α protein as a target for S-nitrosation. FEBS Lett. 535, 106–112 (2003).
Kimura, H. et al. Identification of hypoxia-inducible factor 1 ancillary sequence and its function in vascular endothelial growth factor gene induction by hypoxia and nitric oxide. J. Biol. Chem. 276, 2292–2298 (2001).
Sandau, K. B., Faus, H. G. & Brune, B. Induction of hypoxia-inducible-factor 1 by nitric oxide is mediated via the PI 3K pathway. Biochem. Biophys. Res. Commun. 278, 263–267 (2000).
Kasuno, K. et al. Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling. J. Biol. Chem. 279, 2550–2558 (2004).
Mansfield, K. D. et al. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-α activation. Cell Metab. 1, 393–399 (2005).
Venkataraman, S. et al. Manganese superoxide dismutase overexpression inhibits the growth of androgen-independent prostate cancer cells. Oncogene 24, 77–89 (2005).
Wang, M. et al. Manganese superoxide dismutase suppresses hypoxic induction of hypoxia-inducible factor-1α and vascular endothelial growth factor. Oncogene 24, 8154–8166 (2005).
Liu, Y. et al. Carbon monoxide and nitric oxide suppress the hypoxic induction of vascular endothelial growth factor gene via the 5′ enhancer. J. Biol. Chem. 273, 15257–15262 (1998).
Huang, L. E., Willmore, W. G., Gu, J., Goldberg, M. A. & Bunn, H. F. Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide. Implications for oxygen sensing and signaling. J. Biol. Chem. 274, 9038–9044 (1999).
Hagen, T., Taylor, C. T., Lam, F. & Moncada, S. Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1α. Science 302, 1975–1978 (2003).
Berchner-Pfannschmidt, U., Yamac, H., Trinidad, B. & Fandrey, J. Nitric oxide modulates oxygen sensing by hypoxia-inducible factor 1-dependent induction of prolyl hydroxylase 2. J. Biol. Chem. 282, 1788–1796 (2007).
Jankovic, B. et al. Comparison between pimonidazole binding, oxygen electrode measurements, and expression of endogenous hypoxia markers in cancer of the uterine cervix. Cytometry B Clin. Cytom. 70, 45–55 (2006).
Raleigh, J. A. et al. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res. 58, 3765–3768 (1998).
Vordermark, D. & Brown, J. M. Evaluation of hypoxia-inducible factor-1α (HIF-1α) as an intrinsic marker of tumor hypoxia in U87 MG human glioblastoma: in vitro and xenograft studies. Int. J. Radiat. Oncol. Biol. Phys. 56, 1184–1193 (2003).
Janssen, H. L. et al. HIF-1A, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. Int. J. Radiat. Oncol. Biol. Phys. 54, 1537–1549 (2002).
Quintero, M., Brennan, P. A., Thomas, G. J. & Moncada, S. Nitric oxide is a factor in the stabilization of hypoxia-inducible factor-1α in cancer: role of free radical formation. Cancer Res. 66, 770–774 (2006).
Brown, J. M. & Wilson, W. R. Exploiting tumour hypoxia in cancer treatment. Nature Rev. Cancer 4, 437–447 (2004).
Ljungkvist, A. S., Bussink, J., Kaanders, J. H. & van der Kogel, A. J. Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers. Radiat. Res. 167, 127–145 (2007).
Vaupel, P. & Harrison, L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 9 (Suppl. 5), 4–9 (2004).
Dewhirst, M. W. et al. Quantification of longitudinal tissue pO2 gradients in window chamber tumours: impact on tumour hypoxia. Br. J. Cancer 79, 1717–1722 (1999).
Secomb, T. W., Hsu, R., Dewhirst, M. W., Klitzman, B. & Gross, J. F. Analysis of oxygen transport to tumor tissue by microvascular networks. Int. J. Radiat. Oncol. Biol. Phys. 25, 481–489 (1993).
Secomb, T. W., Hsu, R., Park, E. Y. & Dewhirst, M. W. Green's function methods for analysis of oxygen delivery to tissue by microvascular networks. Ann. Biomed. Eng. 32, 1519–1529 (2004).
Dewhirst, M. W. et al. Microvascular studies on the origins of perfusion-limited hypoxia. Br. J. Cancer Suppl. 27, S247–251 (1996). The first report to demonstrate that arteriolar vasomotion can be involved in intermittent hypoxia.
Erickson, K. et al. Effect of longitudinal oxygen gradients on effectiveness of manipulation of tumor oxygenation. Cancer Res. 63, 4705–4712 (2003).
Sorg, B. S., Moeller, B. J., Donovan, O., Cao, Y. & Dewhirst, M. W. Hyperspectral imaging of hemoglobin saturation in tumor microvasculature and tumor hypoxia development. J. Biomed. Opt. 10, 44004 (2005).
Ljungkvist, A. S. et al. Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 54, 215–228 (2002).
Devasahayam, N. et al. Strategies for improved temporal and spectral resolution in in vivo oximetric imaging using time-domain EPR. Magn. Reson. Med. 57, 776–783 (2007).
Wijffels, K. I. et al. Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas. Br. J. Cancer 83, 674–683 (2000).
Brown, J. M. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br. J. Radiol 52, 650–656 (1979). The first report that intermittent hypoxia that is radiobiologically important can be found in tumours.
Reinhold, H. S., Blachiwiecz, B. & Blok, A. Oxygenation and reoxygenation in 'sandwich' tumours. Bibl. Anat, 270–272 (1977).
Yamaura, H. & Matsuzawa, T. Tumor regrowth after irradiation; an experimental approach. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 35, 201–219 (1979).
Dewhirst, M. W. Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting. Cancer Res. 67, 854–855 (2007).
Durand, R. E. & Aquino-Parsons, C. Clinical relevance of intermittent tumour blood flow. Acta Oncol. 40, 929–936 (2001).
Chaplin, D. J., Olive, P. L. & Durand, R. E. Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res. 47, 597–601 (1987).
Chaplin, D. J., Trotter, M. J., Durand, R. E., Olive, P. L. & Minchinton, A. I. Evidence for intermittent radiobiological hypoxia in experimental tumour systems. Biomed. Biochim. Acta 48, S255–259 (1989).
Minchinton, A. I., Durand, R. E. & Chaplin, D. J. Intermittent blood flow in the KHT sarcoma — flow cytometry studies using Hoechst 33342. Br. J. Cancer 62, 195–200 (1990).
Thomas, C. D., Stern, S., Chaplin, D. J. & Guichard, M. Transient perfusion and radiosensitizing effect after nicotinamide, carbogen, and perflubron emulsion administration. Radiother. Oncol. 39, 235–241 (1996).
Trotter, M. J., Chaplin, D. J. & Olive, P. L. Effect of angiotensin II on intermittent tumour blood flow and acute hypoxia in the murine SCCVII carcinoma. Eur. J. Cancer 27, 887–893 (1991).
Chaplin, D. J., Durand, R. E. & Olive, P. L. Acute hypoxia in tumors: implications for modifiers of radiation effects. Int. J. Radiat. Oncol. Biol. Phys. 12, 1279–1282 (1986).
Durand, R. E. Intermittent blood flow in solid tumours — an under-appreciated source of 'drug resistance'. Cancer Metastasis Rev. 20, 57–61 (2001).
Durand, R. E. & Aquino-Parsons, C. Non-constant tumour blood flow — implications for therapy. Acta Oncol. 40, 862–869 (2001).
Kimura, H. et al. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res. 56, 5522–5528 (1996). The first report to show that intermittent hypoxia can be caused by instabilities in tumour microvessel red cell flux and that vascular stasis is not required for this effect.
Lanzen, J. et al. Direct demonstration of instabilities in oxygen concentrations within the extravascular compartment of an experimental tumor. Cancer Res. 66, 2219–2223 (2006).
Braun, R. D., Lanzen, J. L. & Dewhirst, M. W. Fourier analysis of fluctuations of oxygen tension and blood flow in R3230Ac tumors and muscle in rats. Am. J. Physiol. 277, H551–568 (1999).
Brurberg, K. G., Skogmo, H. K., Graff, B. A., Olsen, D. R. & Rofstad, E. K. Fluctuations in pO2 in poorly and well-oxygenated spontaneous canine tumors before and during fractionated radiation therapy. Radiother. Oncol. 77, 220–226 (2005). The first report that intermittent hypoxia can occur in clinically-relevant canine tumours.
Cardenas-Navia, L. I. et al. Tumor-dependent kinetics of partial pressure of oxygen fluctuations during air and oxygen breathing. Cancer Res. 64, 6010–6017 (2004).
Pigott, K. H., Hill, S. A., Chaplin, D. J. & Saunders, M. I. Microregional fluctuations in perfusion within human tumours detected using laser Doppler flowmetry. Radiother. Oncol. 40, 45–50 (1996).
Bennewith, K. L., Raleigh, J. A. & Durand, R. E. Orally administered pimonidazole to label hypoxic tumor cells. Cancer Res. 62, 6827–6830 (2002).
Cardenas-Navia, L. I. et al. The pervasive presence of fluctuating oxygenation in tumors. Cancer Res. (in the press).
Sorg, B. S., Hardee, M. E., Agarwal, N., Moeller, B. J. & Dewhirst, M. W. Spectral imaging facilitates visualization and measurements of unstable and abnormal microvascular oxygen transport in tumors. J. Biomed. Opt. 13, 014026 (2008).
Baudelet, C. et al. Physiological noise in murine solid tumours using T2*-weighted gradient-echo imaging: a marker of tumour acute hypoxia? Phys. Med. Biol. 49, 3389–3411 (2004).
Brurberg, K. G., Benjaminsen, I. C., Dorum, L. M. & Rofstad, E. K. Fluctuations in tumor blood perfusion assessed by dynamic contrast-enhanced MRI. Magn. Reson. Med. 58, 473–481 (2007).
Baudelet, C. et al. The role of vessel maturation and vessel functionality in spontaneous fluctuations of T2*-weighted GRE signal within tumors. NMR Biomed. 19, 69–76 (2006).
Patan, S., Munn, L. L. & Jain, R. K. Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. Microvasc. Res. 51, 260–272 (1996). This paper is the first to connect the concept of vascular remodelling as a putative mechanism for intermittent hypoxia.
Chien, S., Usami, S. & Skalak, R. in Handbook of Physiology (eds Renkin, E. M., Michel, C. & Geiger, S. R.) 217–251 (American Physiological Society, Bethesda, 1984).
Kiani, M. F., Pries, A. R., Hsu, L. L., Sarelius, I. H. & Cokelet, G. R. Fluctuations in microvascular blood flow parameters caused by hemodynamic mechanisms. Am. J. Physiol. 266, H1822–H1828 (1994).
Pries, A. R., Schonfeld, D., Gaehtgens, P., Kiani, M. F. & Cokelet, G. R. Diameter variability and microvascular flow resistance. Am. J. Physiol. 272, H2716–H2725 (1997).
Kavanagh, B. D., Coffey, B. E., Needham, D., Hochmuth, R. M. & Dewhirst, M. W. The effect of flunarizine on erythrocyte suspension viscosity under conditions of extreme hypoxia, low pH, and lactate treatment. Br. J. Cancer 67, 734–741 (1993).
Cao, Y. et al. Observation of incipient tumor angiogenesis that is independent of hypoxia and hypoxia inducible factor-1 activation. Cancer Res. 65, 5498–5505 (2005). This paper provides evidence in a preclinical model that hypoxia is not a prerequisite for the initiation of tumour angiogenesis.
Nehmeh, S. A. et al. Reproducibility of intratumor distribution of 18F-fluoromisonidazole in head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 70, 235–242 (2008).
Peng, Y. J. et al. Heterozygous HIF-1α deficiency impairs carotid body-mediated systemic responses and reactive oxygen species generation in mice exposed to intermittent hypoxia. J. Physiol. 577, 705–716 (2006).
Yuan, G., Nanduri, J., Bhasker, C. R., Semenza, G. L. & Prabhakar, N. R. Ca2+/calmodulin kinase-dependent activation of hypoxia inducible factor 1 transcriptional activity in cells subjected to intermittent hypoxia. J. Biol. Chem. 280, 4321–4328 (2005).
Semenza, G. L. & Prabhakar, N. R. HIF-1-dependent respiratory, cardiovascular, and redox responses to chronic intermittent hypoxia. Antioxid. Redox Signal. 9, 1391–1396 (2007).
Toffoli, S., Feron, O., Raes, M. & Michiels, C. Intermittent hypoxia changes HIF-1α phosphorylation pattern in endothelial cells: unravelling of a new PKA-dependent regulation of HIF-1α. Biochim. Biophys. Acta 1773, 1558–1571 (2007).
Martinive, P. et al. Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res. 66, 11736–11744 (2006). This report shows that HIF1 upregulation is more strongly induced by repeated exposures to hypoxia–reoxygenation than by chronic hypoxia.
Sioussat, T. M., Dvorak, H. F., Brock, T. A. & Senger, D. R. Inhibition of vascular permeability factor (vascular endothelial growth factor) with antipeptide antibodies. Arch. Biochem. Biophys. 301, 15–20 (1993).
Senger, D. R., Perruzzi, C. A., Feder, J. & Dvorak, H. F. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res. 46, 5629–5632 (1986).
Ferrara, N. & Henzel, W. J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun 161, 851–858 (1989). This is the first report that VEGF is a mitogen for endothelial cells.
Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V. & Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306–1309 (1989).
Yuan, F. et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl Acad. Sci. USA 93, 14765–14770 (1996).
Holash, J. et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284, 1994–1998 (1999). This report is the first to theorize that a hypoxic crisis, mediated by regression of coopted host microvasculature, may be required for tumour angiogenesis initiation.
Holash, J., Wiegand, S. J. & Yancopoulos, G. D. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18, 5356–5362 (1999).
Lin, P. et al. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J. Clin. Invest. 100, 2072–2078 (1997). This is the first paper demonstrating the importance of TIE2, the receptor for angiopoietins, as a pro-angiogenic endothelial cell receptor in tumours.
Peters, K. G. et al. Functional significance of Tie2 signaling in the adult vasculature. Recent Prog. Horm. Res. 59, 51–71 (2004).
Winkles, J. A. et al. Human vascular smooth muscle cells both express and respond to heparin-binding growth factor I (endothelial cell growth factor). Proc. Natl Acad. Sci. USA 84, 7124–7128 (1987).
Soker, S., Takashima, S., Miao, H. Q., Neufeld, G. & Klagsbrun, M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 735–745 (1998).
Mazure, N. M., Chen, E. Y., Yeh, P., Laderoute, K. R. & Giaccia, A. J. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res. 56, 3436–3440 (1996).
Diaz-Gonzalez, J. A., Russell, J., Rouzaut, A., Gil-Bazo, I. & Montuenga, L. Targeting hypoxia and angiogenesis through HIF-1α inhibition. Cancer Biol. Ther. 4, 1055–1062 (2005).
Laderoute, K. R. et al. Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor. Clin. Cancer Res. 6, 2941–2950 (2000).
Steinman, S., Wang, J., Bourne, P., Yang, Q. & Tang, P. Expression of cytokeratin markers, ER-α, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann. Clin. Lab. Sci. 37, 127–134 (2007).
Dabbs, D. J., Chivukula, M., Carter, G. & Bhargava, R. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod. Pathol. 19, 1506–1511 (2006).
Kamat, C. D. et al. Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia. Cancer Lett. 249, 209–219 (2007).
Zhou, S. et al. Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc. Natl Acad. Sci. USA 104, 7540–7545 (2007).
Feldkamp, M. M., Lau, N., Rak, J., Kerbel, R. S. & Guha, A. Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. Int. J. Cancer 81, 118–124 (1999).
Jiang, B. H. & Liu, L. Z. AKT signaling in regulating angiogenesis. Curr. Cancer Drug Targets 8, 19–26 (2008).
Naumov, G. N. et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J. Natl Cancer Inst. 98, 316–325 (2006).
Stessels, F. et al. Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br. J. Cancer 90, 1429–1436 (2004). The first report that vessel cooption can occur in human cancer.
Colpaert, C. G. et al. Cutaneous breast cancer deposits show distinct growth patterns with different degrees of angiogenesis, hypoxia and fibrin deposition. Histopathology 42, 530–540 (2003).
Bos, R. et al. Levels of hypoxia-inducible factor-1 α during breast carcinogenesis. J. Natl Cancer Inst. 93, 309–314 (2001).
Zakrzewicz, A., Secomb, T. W. & Pries, A. R. Angioadaptation: keeping the vascular system in shape. News Physiol. Sci. 17, 197–201 (2002).
Gregoire, V., Hittelman, W. N., Rosier, J. F. & Milas, L. Chemo-radiotherapy: radiosensitizing nucleoside analogues (review). Oncol. Rep. 6, 949–957 (1999).
Bussink, J., Kaanders, J. H., Rijken, P. F., Raleigh, J. A. & van der Kogel, A. J. Changes in blood perfusion and hypoxia after irradiation of a human squamous cell carcinoma xenograft tumor line. Radiat. Res. 153, 398–404 (2000).
Milas, L., Milross, C. G. & Mason, K. A. Cytotoxic treatments and tumor oxygenation. Cancer J. Sci. Am. 2, 59–60; author reply 60–61 (1996).
Milas, L. et al. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res. 55, 3564–3568 (1995).
Milas, L., Hunter, N., Mason, K. A., Milross, C. & Peters, L. J. Tumor reoxygenation as a mechanism of taxol-induced enhancement of tumor radioresponse. Acta Oncol. 34, 409–412 (1995).
Rubin, P. & Casarett, G. Microcirculation of tumors. II. The supervascularized state of irradiated regressing tumors. Clin. Radiol. 17, 346–355 (1966). This paper was the first to suggest that radiation therapy induced a change in tumour vascular density that would favour increased oxygenation.
Dewhirst, M. W. et al. Heterogeneity in tumor microvascular response to radiation. Int. J. Radiat. Oncol. Biol. Phys 18, 559–568 (1990).
Moeller, B. J., Cao, Y., Li, C. Y. & Dewhirst, M. W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5, 429–441 (2004). This paper demonstrated that tumour reoxygenation after radiotherapy paradoxically led to an increase in HIF1 activity through mechanisms involving free radical generation and stress granule disaggregation.
Moeller, B. J. et al. A manganese porphyrin superoxide dismutase mimetic enhances tumor radioresponsiveness. Int. J. Radiat. Oncol. Biol. Phys. 63, 545–552 (2005).
Moeller, B. J. et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8, 99–110 (2005).
Williams, K. J. et al. Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother. Oncol. 75, 89–98 (2005).
Kedersha, N. L., Gupta, M., Li, W., Miller, I. & Anderson, P. RNA-binding proteins TIA-1 and TIAR link the phosphorylation of eIF-2 α to the assembly of mammalian stress granules. J. Cell Biol. 147, 1431–1442 (1999).
Magnon, C. et al. Radiation and inhibition of angiogenesis by canstatin synergize to induce HIF-1α-mediated tumor apoptotic switch. J. Clin. Invest. 117, 1844–1855 (2007).
Tatum, J. L. et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int. J. Radiat. Biol. 82, 699–757 (2006).
Manzoor, A. A., Yuan, H., Palmer, G. M., Viglianti, B. L. & Dewhirst, M. W. in Molecular Imaging: Principles and Practice (eds Weissleder, R., Gambhir, S. S., Ross, B. D. & Rehemtulla, A.) (BC Decker, Ontario, 2008).
Raleigh, J. A., Dewhirst, M. W. & Thrall, D. E. Measuring tumor hypoxia. Semin. Radiat. Oncol. 6, 37–45 (1996).
Khan, N., Williams, B. B., Hou, H., Li, H. & Swartz, H. M. Repetitive tissue pO2 measurements by electron paramagnetic resonance oximetry: current status and future potential for experimental and clinical studies. Antioxid. Redox Signal. 9, 1169–1182 (2007).
Srinivasan, S. et al. Developments in quantitative oxygen-saturation imaging of breast tissue in vivo using multispectral near-infrared tomography. Antioxid. Redox Signal. 9, 1143–1156 (2007).
Matsumoto, K., Subramanian, S., Murugesan, R., Mitchell, J. B. & Krishna, M. C. Spatially resolved biologic information from in vivo EPRI, OMRI, and MRI. Antioxid. Redox Signal. 9, 1125–1141 (2007).
Koch, C. J. Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5. Methods Enzymol. 352, 3–31 (2002).
Koch, C. J., Evans, S. M. & Lord, E. M. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2, 2, 3, 3, 3-pentafluoropropyl)acetamide]: analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br. J. Cancer 72, 869–874 (1995).
Koch, C. J. & Evans, S. M. Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles. Adv. Exp. Med. Biol. 510, 285–292 (2003).
Padhani, A. R., Krohn, K. A., Lewis, J. S. & Alber, M. Imaging oxygenation of human tumours. Eur. Radiol. 17, 861–872 (2007).
Moon, E. J., Brizel, D. M., Chi, J. T. & Dewhirst, M. W. The potential role of intrinsic hypoxia markers as prognostic variables in cancer. Antioxid. Redox Signal. 9, 1237–1294 (2007).
Le, Q. T. et al. Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 69, 167–175 (2007).
Vaupel, P., Hockel, M. & Mayer, A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid. Redox Signal. 9, 1221–1235 (2007).
Secomb, T. W., Hsu, R., Ong, E. T., Gross, J. F. & Dewhirst, M. W. Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncol. 34, 313–316 (1995).
Dewhirst, M. W., Cao, Y., Li, C. Y. & Moeller, B. Exploring the role of HIF-1 in early angiogenesis and response to radiotherapy. Radiother. Oncol. 83, 249–255 (2007).